• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • NICE green light for Cablivi in rare blood-clotting disorder pharmatimes
    November 16, 2020
    The UK’s National Institute for Health and Care Excellence (NICE) has given a green light to Sanofi’s Cablivi for acquired thrombotic thrombocytopenic purpura (aTTP) – a rare and potentially life-threatening blood clotting disorder.
  • Top novel drug approvals: February 2019 europeanpharmaceuticalreview
    April 12, 2019
    Cablivi and Egaten were the two top novel drugs approved last month, with a focus on parasitic infestation and the rare disorder, aTTP…
  • FDA grants fast-track status for Ablynx’s caplacizumab to treat aTTP pharmaceutical-technology
    July 31, 2017
    Belgian biopharmaceutical company Ablynx has received fast-track designation from the US Food and Drug Administration (FDA) for its caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (aTTP).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service